News Image

Why NYSE:BMY qualifies as a good dividend investing stock.

By Mill Chart

Last update: Jan 4, 2024

Our stock screener has singled out BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as a promising choice for dividend investors. NYSE:BMY not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.

Dividend Analysis for NYSE:BMY

ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:BMY was assigned a score of 7 for dividend:

  • BMY has a Yearly Dividend Yield of 4.69%, which is a nice return.
  • BMY's Dividend Yield is rather good when compared to the industry average which is at 4.29. BMY pays more dividend than 97.03% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.43, BMY pays a better dividend.
  • The dividend of BMY is nicely growing with an annual growth rate of 6.94%!
  • BMY has paid a dividend for at least 10 years, which is a reliable track record.

Health Analysis for NYSE:BMY

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:BMY, the assigned 5 reflects its health status:

  • The Altman-Z score of BMY (2.40) is better than 71.29% of its industry peers.
  • The Debt to FCF ratio of BMY is 3.22, which is a good value as it means it would take BMY, 3.22 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.22, BMY belongs to the best of the industry, outperforming 89.11% of the companies in the same industry.

Profitability Examination for NYSE:BMY

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:BMY has achieved a 8:

  • BMY has a better Return On Assets (9.08%) than 92.57% of its industry peers.
  • The Return On Equity of BMY (28.57%) is better than 94.06% of its industry peers.
  • BMY's Return On Invested Capital of 13.32% is amongst the best of the industry. BMY outperforms 90.59% of its industry peers.
  • The 3 year average ROIC (9.56%) for BMY is below the current ROIC(13.32%), indicating increased profibility in the last year.
  • BMY has a Profit Margin of 18.44%. This is amongst the best in the industry. BMY outperforms 93.56% of its industry peers.
  • In the last couple of years the Profit Margin of BMY has grown nicely.
  • The Operating Margin of BMY (24.00%) is better than 92.08% of its industry peers.
  • BMY has a Gross Margin of 76.70%. This is amongst the best in the industry. BMY outperforms 82.67% of its industry peers.
  • BMY's Gross Margin has improved in the last couple of years.

More Best Dividend stocks can be found in our Best Dividend screener.

For an up to date full fundamental analysis you can check the fundamental report of BMY

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (4/19/2024, 11:40:07 AM)

48.575

+0.28 (+0.57%)

BMY News

News Image5 hours ago - The Motley FoolGot $500? 3 Healthcare Stocks to Buy and Hold Forever

Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.

News Image5 hours ago - Yahoo FinanceGot $500? 3 Healthcare Stocks to Buy and Hold Forever

Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.

News Imagea day ago - AB NewswireNavigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
News Image2 days ago - InvestorPlace3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500

If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential.

News Image2 days ago - The Motley Fool2 High-Yield Dividend Stocks to Buy and Hold for 10 Years

These income stocks look like good options at current levels.

News Image4 days ago - InvestorPlace3 Pharma Stocks That Are Money-Printing Machines in 2024

The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.

News Image4 days ago - BusinessInsider3 Pharma Stocks That Are Money-Printing Machines in 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The future of the U.S. economy appears promising, with robust growth and strong...

News Image4 days ago - Investor's Business DailyNeumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug

The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.

News Image4 days ago - The Motley FoolBetter Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?

News Image4 days ago - Yahoo FinanceBetter Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?

Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?

News Image4 days ago - The Motley FoolBetter Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

News Image7 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY)....

BMY Links
Follow us for more